Literature DB >> 18565432

Adolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa.

Keren Middelkoop1, Landon Myer, Daniella Mark, Sibonisile P Mthimunye, Joalida Smit, Robin Wood, Linda-Gail Bekker.   

Abstract

PURPOSE: The importance of involving adolescents in HIV prevention trials has been recognized, but there have been few experiences reported from sub-Saharan Africa. We analyzed adult and adolescent data from a cohort study conducted to assess the feasibility of involving adolescents and adults in HIV vaccine-related studies.
METHODS: Two hundred HIV-negative participants aged 16 to 40 years were enrolled, including 86 (43%) adolescents. At baseline, sexual risk behavior and willingness to participate (WTP) in future HIV vaccine trials questionnaires were administered. Three monthly HIV counseling, pregnancy, HIV and syphilis tests were performed. Risk questionnaires were repeated at 6 months and WTP at 12 months.
RESULTS: No significant difference in retention between adults (83%) and adolescents (87%) was noted (p = .58). Initially, more adults (40%) reported WTP compared to adolescents (13%) (p < .001). At the end of the study both groups reported higher levels of WTP; increasing to 40% among adolescents. HIV incidence during the study was 9.2 infections per 100 person-years (95% confidence interval [CI]: 4.4-19.2) among adolescents compared to 5.8 (95% CI 2.6-12.9) in adults (p = .42).
CONCLUSIONS: Retention of high-risk HIV-negative adolescents in a cohort study is feasible. Following education, adolescents reported improved WTP. The high HIV incidence rate in adolescents highlights the importance of including this group in prevention trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18565432     DOI: 10.1016/j.jadohealth.2007.11.144

Source DB:  PubMed          Journal:  J Adolesc Health        ISSN: 1054-139X            Impact factor:   5.012


  20 in total

1.  Strategies for conducting adolescent health research in the clinical setting: the Mount Sinai Adolescent Health Center HPV experience.

Authors:  Debra K Braun-Courville; Nicolas F Schlecht; Robert D Burk; Howard D Strickler; Mary Rojas; Elizabeth Lorde-Rollins; Anne Nucci-Sack; Dominic Hollman; L Oriana Linares; Angela Diaz
Journal:  J Pediatr Adolesc Gynecol       Date:  2013-12-12       Impact factor: 1.814

2.  The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women.

Authors:  Rochelle P Walensky; Ji-Eun Park; Robin Wood; Kenneth A Freedberg; Callie A Scott; Linda-Gail Bekker; Elena Losina; Kenneth H Mayer; George R Seage; A David Paltiel
Journal:  Clin Infect Dis       Date:  2012-04-03       Impact factor: 9.079

3.  Adolescent and Parent Perceptions about Participation in Biomedical Sexual Health Trials.

Authors:  Sara E Landers; Jenny K R Francis; Marilyn C Morris; Christine Mauro; Susan L Rosenthal
Journal:  Ethics Hum Res       Date:  2020-05

4.  Willingness to participate in biomedical HIV prevention studies after the HVTN 503/Phambili trial: a survey conducted among adolescents in Soweto, South Africa.

Authors:  Kennedy N Otwombe; Kathleen J Sikkema; Janan Dietrich; Guy de Bruyn; Martin van der Watt; Glenda E Gray
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

5.  Enhancing HIV vaccine trial consent preparedness among street drug users.

Authors:  Celia B Fisher
Journal:  J Empir Res Hum Res Ethics       Date:  2010-06       Impact factor: 1.742

6.  Comprehension of a simplified assent form in a vaccine trial for adolescents.

Authors:  Sonia Lee; Bill G Kapogiannis; Patricia M Flynn; Bret J Rudy; James Bethel; Sushma Ahmad; Diane Tucker; Sue Ellen Abdalian; Dannie Hoffman; Craig M Wilson; Coleen K Cunningham
Journal:  J Med Ethics       Date:  2013-01-24       Impact factor: 2.903

7.  Issues in women's participation in a phase III community HIV vaccine trial in Thailand.

Authors:  Jaranit Kaewkungwal; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Chirasak Khamboonruang; Prayura Kunasol; Pravan Suntharasamai; Swangjai Pungpak; Sirivan Vanijanonta; Valai Bussaratid; Wirach Maek-A-Nantawat; Jittima Dhitavat; Prasert Thongcharoen; Rungrawee Pawarana; Yupa Sabmee; Mike W Benenson; Patricia Morgan; Robert J O'Connell; Jerome Kim
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-25       Impact factor: 2.205

8.  Inclusion of South African adolescents in HIV vaccine trials.

Authors:  David H Adler
Journal:  J AIDS HIV Res       Date:  2012-02-01

9.  Preparing for the unexpected: the pivotal role of social and behavioral sciences in trials of biomedical HIV prevention interventions.

Authors:  Beryl A Koblin; Michele Andrasik; Judy Austin
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07       Impact factor: 3.731

10.  PrEP Implementation Science: State-of-the-Art and Research Agenda.

Authors:  Carlos F Cáceres; Kenneth H Mayer; Rachel Baggaley; Kevin R O'Reilly
Journal:  J Int AIDS Soc       Date:  2015-07-20       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.